Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer

Abstract

To investigate the relationships between the expression of MUC5B and clinicopathological parameters, the expression of MUC5B was immunohistochemically studied. MUC5B expression was observed in 129 of 198 (65.2%) adenocarcinomas and in 4 of 49 (8.2%) squamous cell carcinomas (P < 0.00001). MUC5B expression was significantly associated with poorer differentiation (P = 0.0303), higher pathological TNM stage (p = 0.0153) and poorer prognosis of adenocarcinoma patients (P = 0.0017). Multivariable analysis with Cox proportional hazards models confirmed that MUC5B expression increased the hazard of death after adjusting for other clinicopathological factors (HR = 2.66; 95%CI, 1.26–5.61). We also immunohistochemically evaluated TTF-1 expression and found that the combination of MUC5B with TTF-1 is a useful marker for adenocarcinomas. The diagnostic accuracies of TTF-1 and MUC5B for adenocarcinoma were 83.8% and 70.4%, respectively. The accuracy increased to 94.3% when the two factors were combined. In survival analysis, the MUC5B(High)/TTF-1(−) group was significantly associated with a poorer outcome compared with the MUC5B(Low)/TTF-1(+) group (p < 0.0001). The present study suggested that the combination of MUC5B and TTF-1 expression is useful for discriminating adenocarcinomas from squamous cell carcinomas, yielding prognostic significance in patients with lung adenocarcinoma.

Targeted Expression of miR-7 Operated by TTF-1 Promoter Inhibited the Growth of Human Lung Cancer through the NDUFA4 Pathway

“…To verify this phenomenon, we also detected the expression of TTF-1 in these cancer cells, which also valuably reflected the intrinsic activity of TTF-1 promoter. Consistently, we found that the expression level of TTF-1 was also higher in lung cancer cells than that in other cancer cells, which was consistent with previous finding that TTF-1 was dominantly expressed in lung cancer cells, but not other types of cancer cells 24, 25, 26…”

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs

“…Recent studies with diagnoses based on the previous 2004 WHO classification, have shown that 64% to 86% of lung AC cases are positive for the TTF-1 clone 8G7G3/1 whereas 72% to 89% are positive for the TTF-1 clone SPT24 and 77% to 90% for napsin A. 14,15,[25][26][27][28][29][30][31][32][33][34][35] Mucinous and solid predominant ACs are more frequently negative, 26,28,[36][37][38] and they constituted 28% and 40% of the IHC-negative AC cases in our material, respectively. Likewise, studies have shown that 79% to 94% of lung SCC cases are positive for CK5 (or CK5/6), 76% to 100% for p40, and 87% to 100% for p63.…”

Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma

“…Thus, a further understanding of the tumorigenesis and biology of lung cancer might be useful for the development of novel prognostic markers or therapeutic targets in lung adenocarcinoma. We previously generated monoclonal antibodies to tumor‐associated proteins using lung cancer cells or tissues, termed the random immunization method . The present study describes one antibody, designated KU‐Lu‐10, which recognizes the inner membrane mitochondrial protein (IMMT) by immunoprecipitation and mass spectrometry (Supplementary Data S1 and Fig S1).…”

“…We previously generated monoclonal antibodies to tumor-associated proteins using lung cancer cells or tissues, termed the random immunization method. [2][3][4] The present study describes one antibody, designated KU-Lu-10, which recognizes the inner membrane mitochondrial protein (IMMT) by immunoprecipitation and mass spectrometry (Supplementary Data S1 and Fig S1).…”